Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2015 · 10-Q
Revenue$126.11M$126.11M+14.3% vs Q2 2014 Net Income$14.10M$14.10M+180.4% vs Q2 2014 EPS Diluted$0.32$0.32+146.2% vs Q2 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,503,000−76.9% Free Cash Flowderived-$8,096,000N/M Margins · derivedGross margin27.8%
Operating margin17.0%+9.9 pt vs Q2 2014
Net margin11.2%+6.6 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 6, 2015 · 37 d after period end